Table 2. Antigen levels (ng mg−1 protein) of MMP-2, MMP-7, MMP-8 and MMP-9 and of inhibitors TIMP-1 and TIMP-2 in normal mucosa and carcinoma of 81 patients with gastric cancer.
| Mucosa | Carcinoma | P-value | |
|---|---|---|---|
| MMP-2 | |||
| Antigen | 4.7±0.4 | 17.0±2.0 | ⩽0.001 |
| Total activitya | 81.1±23.6 | 185.7±45.5 | ⩽0.001 |
| Pro-forma | 78.9±23.6 | 181.1±45.3 | 0.001 |
| Activea | 2.3±0.5 | 4.7±1.1 | 0.02 |
| MMP-9 | |||
| Antigen | 9.0±0.9 | 24.7±2.3 | ⩽0.001 |
| Total activitya | 67.5±6.0 | 128.8±11.3 | ⩽0.001 |
| Pro-forma | 59.9±5.6 | 117.1±10.1 | ⩽0.001 |
| Activea | 7.6±1.5 | 9.5±2.1 | NS |
| MMP-7 | 2.0±0.5 | 47.1±12.4 | 0.002 |
| MMP-8 | 95±12 | 319±47 | ⩽0.001 |
| TIMP-1 | 8.0±0.8 | 16.9±1.3 | ⩽0.001 |
| TIMP-2 | 5.9±0.2 | 6.3±0.4 | NS |
Mean±s.e.m.
Bioactivity assay levels of MMP-2 and MMP-9 are expressed as units per mg protein.
a
As determined by BIA.
MMP=matrix metalloproteinase; BIA=bioactivity assay; TIMP=tissue inhibitors of MMP.